RenovoRx Company Research Report

Company Overview

Name

RenovoRx, Inc.

Mission of the Company

RenovoRx is committed to developing transformative therapies for improved quality of life and extended life in cancer patients, aiming to deliver therapy where it matters.

Founding

Founders: Ramtin Agah, MD

Founded: No information is available

Key People in the Company

Shaun R. Bagai - Chief Executive Officer

Ramtin Agah, MD - Chief Medical Officer, Founder

Leesa Gentry - Chief Clinical Officer

Ronald B. Kocak, CPA - VP Controller and Principal Accounting Officer

Ryan Witt - Senior Vice President, Head of Corporate Strategy and Partnerships

Imtiaz Qureshi, MD - Director of Imaging

Board of Directors

Ramtin Agah, MD - Chairman

Shaun R. Bagai - Director

Angela Macfarlane - Director

Laurence J. Marton, MD - Director

Una S. Ryan, PhD, OBE - Director

Robert J. Spiegel - Director

Headquarters

4546 El Camino Real, Suite B1, Los Altos, CA 94022

Number of Employees

No information is available

Revenue

No information is available

Known For

RenovoRx is known for developing proprietary targeted combination therapies for challenging-to-treat cancers leveraging their TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform.

Products

Product Offerings

RenovoGem™: A novel oncology drug-device combination product designed for the targeted treatment of Locally Advanced Pancreatic Cancer (LAPC). This product utilizes the RenovoRx TAMP™ therapy platform to deliver gemcitabine (chemotherapy) precisely to the tumor site.

Key Features

RenovoGem™:

Therapy Platform: TAMP™ (Trans-Arterial Micro-Perfusion)

Unique Approach: Targeted trans-arterial delivery via isolated blood vessel sections using a double-balloon system for treatment precision.

Safety and Efficacy: Designed to increase safety and decrease therapy-related toxicities compared to systemic chemotherapy.

Recent Developments

New Products Launched

No new product launches reported as per the available data.

Recent Developments and New Features

RenovoCath® Delivery System: Increased production in response to strong market demand for standalone use in clinical practices.

TIGeR-PaC Clinical Trial: Ongoing pivotal Phase III trial for Locally Advanced Pancreatic Cancer using TAMP™ with promising clinical feedback.

Partnerships: Expanded relationship with manufacturing partner Medical Murray, including provisioning warrants based on manufacturing milestones.

Presentations and Publications:

Clinical data presented at the Symposium on Clinical Interventional Oncology in 2024.

Publication of positive early-stage clinical data in international journals highlighting the efficacy and potential of the TAMP™ platform.

Leadership Developments: Robert Strasser promoted to Vice President of R&D and Operations to support manufacturing and scale production capabilities.

Strategic Collaborations

Formation of new project work order with Medical Murray to enhance manufacturing capacities and explore commercial opportunities for RenovoCath beyond the current clinical trials.